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Dr. Eric Haura discussed the role of aberrant nonreceptortyrosine Src kinase signaling in carcinogenesis. There
are nine members in the Src-family kinases (SFKs), namely
c-Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk, and Yrk. SFKs can
interact bidirectionally with various receptor tyrosine kinases
such as epidermal growth factor receptor (EGFR) and vascu-
lar endothelial growth factor receptor to mediate downstream
oncogenic processes. Of particular interest is c-Src, high
levels of which are found in a number of malignancies
including lung cancer.1 Dephosphorylation of Y530 residue
at the negative regulatory C-terminal site or autophosphory-
lation at Y419 of the SH1 domain leads to an activated
conformation. Activated c-Src can regulate cell motility and
invasion through the cytoskeletal network by forming a
complex with focal adhesion kinase, which then activates
multiple other signaling pathways such as integrin, Ras, and
phosphatidylinositol 3-kinase/Akt.2 Activated c-Src leads to
functional loss of E-cadherin,3 a tumor suppressor that regu-
lates epithelial-mesenchymal transition. Emergence of epi-
thelial-mesenchymal transition has been implicated as one of
the mechanisms of resistance to EGFR tyrosine kinase inhib-
itors.4 In addition, Src plays a central role in regulating
osteoclastic activity and in mediating tumor-associated bone
destruction.5,6 Src inhibitors in clinical development currently
include dasatinib (BMS-354825), bosutinib (SKI-606), and
saracatinib (AZD0530).
Dasatinib is an orally administered multitargeted agent
that inhibits SFKs, BCR-ABL, c-Kit, platelet derived growth
factor receptor, and Eph receptors. It induces concentration-
dependent apoptosis in non-small cell lung cancer (NSCLC)
cell lines that harbor activating EGFR tyrosine kinase muta-
tions. In cell lines with wild-type or gefitinib-resistant EGFR
mutations, dasatinib induces cell cycle arrest and prevents
tumor invasion.7 Recommended phase II dose is 70 mg twice
daily. Preliminary report of its single-agent activity in the
front-line setting has demonstrated objective tumor responses
though there is no clear association between EGFR and Kras
mutational status, at least in part due to small sample size
studied to date.8 Another phase II study of dasatinib in
patients with previously treated NSCLC is currently ongoing
(NCT00787267). A phase IB study of the combination of
erlotinib with dasatinib in NSCLC has been recently pub-
lished.9 Prior therapy with any EGFR-targeting agent or with
dasatinib is an exclusion criteria. The combination is tolera-
ble at the full single-agent doses with no appreciable phar-
macokinetic interaction observed. Partial responses were seen
in 2 of 34 patients, one with EGFR wild-type squamous cell
carcinoma and another patient with EGFR mutant adenocar-
cinoma. Another patient with stable disease exhibited scle-
rotic response to multiple bone metastases. A phase II study
of dasatinib as second-line treatment for small cell lung
cancer in chemosensitive relapse was terminated early due to
lack of activity. Dasatinib is also currently being tested by
CALGB in a phase II setting as second-line monotherapy in
patients with previously treated MM.10
Dr. Anne Tsao presented data on saracatinib
(AZD0530), an orally administered, potent selective revers-
ible inhibitor of SFK with dual inhibitory activity against the
Abl kinase as well. It demonstrates antiproliferative effects
against a number of cancer cell lines including NSCLC both
in vitro and in vivo.11 It has radiosensitizing properties and
can augment the antitumor activity of various agents.12,13 It
has favorable PK and bioavailability suitable for once daily
dosing with no appreciable food effect. The recommended
phase II dose is 175 mg once daily.14 A phase II study of
saracatinib as maintenance therapy for patients with extensive
stage small cell lung cancer after four cycles of cytoreductive
chemotherapy has completed enrollment. Further develop-
ment of this agent has been discontinued as preliminary
results from ovarian cancer and pancreatic cancer studies
suggest lack of efficacy. Recruitment will be completed for
currently open trials such as a phase II study of saracatinib as
maintenance therapy for advanced NSCLC after completing
front-line platinum-based regimen (NCT00638937) and as
salvage therapy for patients with relapsed or refractory thy-
mic malignancies (NCT00718809).
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